Maharashtra FDA Complaints Surge 557 Per Cent To 1,397 In 3 Months As Drug Enforcement Intensifies
Mumbai, September 12, 2026: For consumers buying medicines in Maharashtra, the risk of encountering drugs being sold without prescriptions, medicines making unauthorised claims or products that do not meet quality standards appears to be under increased scrutiny, with the Food and Drug Administration (FDA) receiving 1,397 complaints in just three months from June to August 2026—a 557% rise over…
Mumbai, September 12, 2026: Complaints to the Maharashtra FDA have surged 557% to 1,397 in just three months, with an intensified focus on drugs sold without prescriptions and products lacking quality standards. This significant increase in complaints occurred as Tukaram Mundhe took charge as FDA Commissioner. Out of the 1,397 complaints received, 924 were investigated, a 378% rise compared to the previous quarterly average.
The FDA has also stepped up enforcement, with seizure action increasing by 217% and the value of seized material reaching Rs 11.41 crore, a 234% rise. The department registered 20 FIRs, about 21% higher than the quarterly average. The majority of complaints involved allopathic medicines sold without prescriptions, followed by Ayurvedic medicines with unauthorised claims.
Routine inspections uncovered various violations at drug and cosmetic manufacturing units, including lack of competent technical staff, unauthorised personnel in batch records, testing without qualified QC staff, missing Annual Product Quality Reviews, and discrepancies in sterilisation records. Between June and August 2026, the FDA conducted 2,902 inspections and took action in 880 cases, including 677 licence suspensions and 203 cancellations.
Written by urgent.news from Free Press Journal's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
